Omid Hamid, MD

The professor from Cedars Sinai discussed further research being conducted in the field after lifileucel’s approval.

The professor from Cedars Sinai also discussed additional investigations evaluating lifileucel for other advanced subtypes of melanoma.

The professor from Cedars Sinai discussed data he is anticipating from further investigations into lifileucel.

The professor from Cedars Sinai discussed how the cell therapy stands to revolutionize the treatment landscape.

The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed the efficacy of TIL therapy following immunotherapy in advanced melanoma.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed evaluation criteria for TIL therapy in melanoma.